Inventor · disambiguated record
Raymond D. Skwierczynski
Also filed as: SKWIERCZYNSKI RAYMOND · SKWIERCZYNSKI RAYMOND D
20 granted patents·22 pending applications·801 citations·filing 2000–2023
95Inventor score
Files withMILLENNIUM PHARM INC19TREMEAU PHARMACEUTICALS INC113M INNOVATIVE PROPERTIES CO5TAKEDA PHARMACEUTICAL2COLUCID PHARMACEUTICALS INC1
Top patents by PatentIndex Score
42 records- 0197US6486168B1Formulations and methods for treatment of mucosal associated conditions with an immune response modifier3M INNOVATIVE PROPERTIES CO·Filed 2000·Granted Nov 26, 2002·217 cites·16 claims
- 0297US6245776B1Formulations and methods for treatment of mucosal associated conditions with an immune response modifier3M INNOVATIVE PROPERTIES CO·Filed 2000·Granted Jun 12, 2001·456 cites·22 claims
- 0395US8859504B2Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2012·Granted Oct 14, 2014·29 cites·15 claims
- 0494US10987337B2Purified forms of rofecoxib, methods of manufacture and useTREMEAU PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·9 cites·28 claims
- 0593US11617735B2Purified forms of rofecoxib, methods of manufacture and useTREMEAU PHARMACEUTICALS INC·Filed 2022·Granted Apr 4, 2023·2 cites·28 claims
- 0693US11559509B2Purified forms of rofecoxib, methods of manufacture and useTREMEAU PHARMACEUTICALS INC·Filed 2022·Granted Jan 24, 2023·2 cites·25 claims
- 0792US10945992B1Dosage forms of rofecoxib and related methodsTREMEAU PHARMACEUTICALS INC·Filed 2020·Granted Mar 16, 2021·6 cites·28 claims
- 0892US9175018B2Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2014·Granted Nov 3, 2015·12 cites·40 claims
- 0991US11576890B2Purified forms of rofecoxib, methods of manufacture and useTREMEAU PHARMACEUTICALS INC·Filed 2021·Granted Feb 14, 2023·2 cites·32 claims
- 1091US11485746B2Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2020·Granted Nov 1, 2022·2 cites·14 claims
- 1191US7968562B2Pharmaceutical formulations comprising an immune response modifier3M INNOVATIVE PROPERTIES CO·Filed 2008·Granted Jun 28, 2011·43 cites·12 claims
- 1287US9175017B2Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2014·Granted Nov 3, 2015·5 cites·13 claims
- 1387US2023265111A1Boronate ester compounds and pharmaceutical compositions thereofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1486US10604538B2Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2019·Granted Mar 31, 2020·2 cites·1 claims
- 1586US10526351B2Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2019·Granted Jan 7, 2020·2 cites·1 claims
- 1680US11872206B2Purified forms of rofecoxib, methods of manufacture and useTREMEAU PHARMACEUTICALS INC·Filed 2022·Granted Jan 16, 2024·0 cites·36 claims
- 1780US2022009948A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2021·Application pending·0 cites
- 1878US2021198289A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2021·Application pending·0 cites
- 1977US9504693B2Pharmaceutical compositions for the treatment of cancer and other diseases or disordersMILLENNIUM PHARM INC·Filed 2015·Granted Nov 29, 2016·3 cites·20 claims
- 2076US9127011B2Pharmaceutical compositions for the treatment of cancer and other diseases or disordersMILLENNIUM PHARM INC·Filed 2013·Granted Sep 8, 2015·4 cites·17 claims
- 2176US2020392164A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2020·Application pending·0 cites
- 2274US2020181176A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2020·Application pending·0 cites
- 2373US2022409575A1Dosage forms of rofecoxib and related methodsTREMEAU PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2472US2019263839A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2019·Application pending·0 cites
- 2571US9248127B2Aqueous gel formulations containing immune response modifiersPERMAN CHRISTOPHER S·Filed 2006·Granted Feb 2, 2016·5 cites·18 claims
- 2671US2022047542A1Novel dosage forms of rofecoxib and related methodsTREMEAU PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2771US2019048028A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 2870US2009325903A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 2969US2018208609A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 3068US2021169845A1Novel dosage forms of rofecoxib and related methodsTREMEAU PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3168US2018002350A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2017·Application pending·0 cites
- 3267US2021137878A1Novel dosage forms of rofecoxib and related methodsTREMEAU PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3362US2024218365A1Formulation of an antisense oligomer conjugateSAREPTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3462US2016031913A1Boronate ester compounds and pharmaceutical compositions thereofMILLENNIUM PHARM INC·Filed 2015·Application pending·0 cites
- 3558US2022125773A1Aqueous formulations of water insoluble cox-2 inhibitorsTREMEAU PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3652US11053214B2Compositions and methods related to pyridinoylpiperidine 5-HT1F agonistsCOLUCID PHARMACEUTICALS INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 3744US2003199538A1Pharmaceutical formulation comprising an immune response modifier3M INNOVATIVE PROPERTIES CO·Filed 2002·Application pending·0 cites
- 3844US2011039826A1Pharmaceutical compositions for the treatment of cancer and other diseases or disordersMILLENNIUM PHARM INC·Filed 2010·Application pending·0 cites
- 3944US2009124652A1Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-SulfonateTAKEDA PHARMACEUTICAL·Filed 2005·Application pending·0 cites
- 4043US10071156B2Aqueous gel formulations containing immune response modifiers3M INNOVATIVE PROPERTIES CO·Filed 2015·Granted Sep 11, 2018·0 cites·24 claims
- 4138US2008207675A1Aqueous Gel Formulations Containing 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-AmineTAKEDA PHARMACEUTICAL·Filed 2006·Application pending·0 cites
- 4236US2008188513A11-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine MethanesulfonateTAKED PHARMACEUTICAL COMPANY L·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Raymond D. Skwierczynski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →